Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Bowel Diseases | 17 | 2022 | 549 | 3.260 |
Why?
|
Capsule Endoscopy | 4 | 2023 | 33 | 2.610 |
Why?
|
Colitis, Ulcerative | 13 | 2024 | 711 | 2.460 |
Why?
|
Liver Diseases | 4 | 2021 | 238 | 1.620 |
Why?
|
Gastrointestinal Hemorrhage | 8 | 2023 | 229 | 1.530 |
Why?
|
Short Bowel Syndrome | 2 | 2020 | 37 | 1.450 |
Why?
|
Nutrition Therapy | 2 | 2020 | 11 | 1.390 |
Why?
|
Intestinal Diseases | 3 | 2020 | 79 | 1.390 |
Why?
|
Crohn Disease | 9 | 2022 | 730 | 1.280 |
Why?
|
Parenteral Nutrition | 4 | 2024 | 60 | 1.260 |
Why?
|
Clostridium Infections | 6 | 2022 | 125 | 1.190 |
Why?
|
Neoplasms | 7 | 2024 | 2898 | 1.080 |
Why?
|
Biosimilar Pharmaceuticals | 4 | 2020 | 20 | 1.070 |
Why?
|
Humans | 86 | 2024 | 86643 | 1.050 |
Why?
|
Gastrointestinal Agents | 4 | 2020 | 161 | 0.990 |
Why?
|
Autoimmune Diseases | 7 | 2021 | 241 | 0.980 |
Why?
|
Nutrition Assessment | 2 | 2021 | 21 | 0.960 |
Why?
|
Rheumatic Diseases | 2 | 2021 | 20 | 0.960 |
Why?
|
Hospitalization | 8 | 2023 | 849 | 0.950 |
Why?
|
Gastroenterology | 2 | 2018 | 134 | 0.950 |
Why?
|
Infliximab | 4 | 2020 | 151 | 0.920 |
Why?
|
Vaccination | 2 | 2022 | 254 | 0.900 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2023 | 19 | 0.900 |
Why?
|
Retrospective Studies | 19 | 2024 | 8489 | 0.890 |
Why?
|
Colitis | 3 | 2021 | 239 | 0.890 |
Why?
|
Enterocolitis | 1 | 2022 | 12 | 0.870 |
Why?
|
Opportunistic Infections | 1 | 2022 | 59 | 0.840 |
Why?
|
Peritoneal Neoplasms | 2 | 2023 | 177 | 0.840 |
Why?
|
Patient Readmission | 4 | 2024 | 329 | 0.840 |
Why?
|
Intestine, Small | 3 | 2023 | 303 | 0.820 |
Why?
|
Cathartics | 1 | 2021 | 27 | 0.820 |
Why?
|
Cytomegalovirus Infections | 1 | 2022 | 144 | 0.810 |
Why?
|
Immune System Diseases | 2 | 2019 | 26 | 0.810 |
Why?
|
Endoscopy, Gastrointestinal | 2 | 2021 | 153 | 0.800 |
Why?
|
Enterocolitis, Pseudomembranous | 7 | 2015 | 52 | 0.790 |
Why?
|
Vaccines | 1 | 2022 | 80 | 0.790 |
Why?
|
Malnutrition | 1 | 2021 | 34 | 0.760 |
Why?
|
Liver | 3 | 2021 | 1230 | 0.760 |
Why?
|
Nasturtium | 1 | 2020 | 4 | 0.750 |
Why?
|
Fasciola hepatica | 1 | 2020 | 5 | 0.750 |
Why?
|
Antibodies, Helminth | 1 | 2020 | 11 | 0.750 |
Why?
|
Fascioliasis | 1 | 2020 | 6 | 0.750 |
Why?
|
Dyspepsia | 1 | 2020 | 10 | 0.750 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 105 | 0.740 |
Why?
|
Angiodysplasia | 1 | 2019 | 4 | 0.720 |
Why?
|
Spiders | 1 | 2019 | 14 | 0.710 |
Why?
|
Eosinophilia | 1 | 2020 | 84 | 0.710 |
Why?
|
Bone Resorption | 1 | 2019 | 41 | 0.700 |
Why?
|
Biological Products | 1 | 2021 | 143 | 0.700 |
Why?
|
Risk Factors | 17 | 2024 | 5417 | 0.690 |
Why?
|
Bone Diseases, Metabolic | 1 | 2019 | 33 | 0.690 |
Why?
|
Intestinal Neoplasms | 1 | 2019 | 56 | 0.690 |
Why?
|
Bariatric Surgery | 1 | 2021 | 194 | 0.670 |
Why?
|
Osteoporosis | 2 | 2019 | 121 | 0.670 |
Why?
|
Central Venous Catheters | 1 | 2019 | 23 | 0.670 |
Why?
|
Organ Transplantation | 1 | 2022 | 265 | 0.660 |
Why?
|
Organometallic Compounds | 1 | 2019 | 132 | 0.660 |
Why?
|
Nutritional Sciences | 1 | 2018 | 12 | 0.640 |
Why?
|
Lymphatic Metastasis | 1 | 2019 | 486 | 0.620 |
Why?
|
Osteogenesis | 1 | 2019 | 242 | 0.620 |
Why?
|
Gastroenterologists | 1 | 2018 | 30 | 0.610 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.600 |
Why?
|
Intensive Care Units | 1 | 2020 | 373 | 0.600 |
Why?
|
Tumor Necrosis Factor-alpha | 5 | 2019 | 683 | 0.600 |
Why?
|
Diet | 1 | 2020 | 443 | 0.580 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 108 | 0.580 |
Why?
|
Mediastinal Diseases | 1 | 2016 | 21 | 0.560 |
Why?
|
Celiac Disease | 1 | 2019 | 203 | 0.560 |
Why?
|
Antibodies, Monoclonal | 7 | 2021 | 1376 | 0.560 |
Why?
|
Granuloma | 1 | 2016 | 65 | 0.560 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.520 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.520 |
Why?
|
Middle Aged | 25 | 2023 | 25028 | 0.510 |
Why?
|
Deglutition Disorders | 1 | 2016 | 115 | 0.510 |
Why?
|
Ileitis | 1 | 2014 | 7 | 0.490 |
Why?
|
Female | 37 | 2023 | 44532 | 0.480 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 369 | 0.470 |
Why?
|
Antibodies, Monoclonal, Humanized | 5 | 2019 | 930 | 0.470 |
Why?
|
Male | 34 | 2023 | 40965 | 0.460 |
Why?
|
Cystic Fibrosis | 3 | 2018 | 112 | 0.460 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2018 | 106 | 0.460 |
Why?
|
Colonoscopy | 5 | 2023 | 264 | 0.460 |
Why?
|
Colorectal Neoplasms | 4 | 2023 | 938 | 0.430 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 1565 | 0.370 |
Why?
|
Adult | 21 | 2021 | 25648 | 0.370 |
Why?
|
Calcineurin Inhibitors | 2 | 2021 | 54 | 0.360 |
Why?
|
Fibrosis | 2 | 2021 | 203 | 0.350 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 92 | 0.350 |
Why?
|
Severity of Illness Index | 7 | 2021 | 1801 | 0.350 |
Why?
|
Aged | 16 | 2023 | 18415 | 0.350 |
Why?
|
Abdominal Pain | 2 | 2020 | 137 | 0.330 |
Why?
|
Antirheumatic Agents | 2 | 2020 | 54 | 0.330 |
Why?
|
Liver Cirrhosis | 3 | 2021 | 297 | 0.320 |
Why?
|
Weight Loss | 3 | 2019 | 229 | 0.320 |
Why?
|
Biopsy | 3 | 2021 | 1163 | 0.310 |
Why?
|
Mesentery | 2 | 2019 | 45 | 0.310 |
Why?
|
Cholangitis, Sclerosing | 2 | 2018 | 52 | 0.300 |
Why?
|
Inpatients | 3 | 2021 | 297 | 0.290 |
Why?
|
Treatment Outcome | 15 | 2020 | 7993 | 0.280 |
Why?
|
Colectomy | 2 | 2024 | 167 | 0.260 |
Why?
|
Gastrointestinal Diseases | 2 | 2017 | 146 | 0.260 |
Why?
|
Prospective Studies | 5 | 2021 | 4213 | 0.260 |
Why?
|
Lung Diseases, Interstitial | 2 | 2020 | 235 | 0.250 |
Why?
|
Risk Assessment | 5 | 2019 | 2261 | 0.240 |
Why?
|
Adenomatous Polyps | 1 | 2023 | 11 | 0.240 |
Why?
|
Cohort Studies | 4 | 2024 | 2767 | 0.240 |
Why?
|
Adolescent, Hospitalized | 1 | 2022 | 1 | 0.230 |
Why?
|
Diarrhea | 2 | 2014 | 182 | 0.220 |
Why?
|
Gastrostomy | 1 | 2023 | 69 | 0.220 |
Why?
|
ROC Curve | 3 | 2021 | 752 | 0.220 |
Why?
|
Hemoglobins | 1 | 2023 | 179 | 0.220 |
Why?
|
Ulcer | 1 | 2022 | 36 | 0.220 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 55 | 0.220 |
Why?
|
Cytomegalovirus | 1 | 2022 | 76 | 0.210 |
Why?
|
Diverticulum | 2 | 2019 | 44 | 0.210 |
Why?
|
Adolescent | 11 | 2022 | 8981 | 0.210 |
Why?
|
Polymerase Chain Reaction | 2 | 2022 | 927 | 0.210 |
Why?
|
Young Adult | 10 | 2019 | 5976 | 0.210 |
Why?
|
Aspartate Aminotransferases | 1 | 2021 | 73 | 0.200 |
Why?
|
Adenoma | 1 | 2023 | 235 | 0.200 |
Why?
|
Platelet Count | 1 | 2021 | 92 | 0.200 |
Why?
|
Hospitals | 1 | 2024 | 294 | 0.200 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2021 | 39 | 0.200 |
Why?
|
Double-Balloon Enteroscopy | 1 | 2021 | 11 | 0.200 |
Why?
|
Prognosis | 5 | 2022 | 3679 | 0.200 |
Why?
|
Propensity Score | 1 | 2021 | 136 | 0.200 |
Why?
|
Gastrointestinal Tract | 1 | 2023 | 191 | 0.190 |
Why?
|
Antibodies, Viral | 1 | 2022 | 293 | 0.190 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2021 | 243 | 0.190 |
Why?
|
Nutritional Status | 1 | 2021 | 83 | 0.190 |
Why?
|
Enteral Nutrition | 1 | 2021 | 102 | 0.190 |
Why?
|
Biomarkers | 4 | 2021 | 1718 | 0.190 |
Why?
|
Antiplatyhelmintic Agents | 1 | 2020 | 6 | 0.190 |
Why?
|
Vitamin D | 2 | 2021 | 261 | 0.190 |
Why?
|
Life Cycle Stages | 1 | 2020 | 16 | 0.190 |
Why?
|
Colonic Polyps | 1 | 2021 | 126 | 0.180 |
Why?
|
Interleukin-23 | 1 | 2020 | 54 | 0.180 |
Why?
|
Aged, 80 and over | 7 | 2023 | 6509 | 0.180 |
Why?
|
Warfarin | 1 | 2020 | 103 | 0.180 |
Why?
|
Lubricants | 1 | 2019 | 7 | 0.180 |
Why?
|
Panniculitis, Peritoneal | 1 | 2019 | 4 | 0.180 |
Why?
|
Laxatives | 1 | 2019 | 13 | 0.180 |
Why?
|
Interleukin-12 | 1 | 2020 | 108 | 0.180 |
Why?
|
Mesenteric Artery, Superior | 1 | 2019 | 19 | 0.180 |
Why?
|
Travel | 1 | 2020 | 68 | 0.180 |
Why?
|
Cyclosporine | 2 | 2018 | 234 | 0.180 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 103 | 0.180 |
Why?
|
Mesenteric Veins | 1 | 2019 | 34 | 0.180 |
Why?
|
Respiratory Tract Infections | 1 | 2020 | 105 | 0.180 |
Why?
|
Drug Substitution | 1 | 2019 | 25 | 0.170 |
Why?
|
Radionuclide Imaging | 1 | 2019 | 220 | 0.170 |
Why?
|
Tacrolimus | 2 | 2018 | 373 | 0.170 |
Why?
|
Diet, Gluten-Free | 1 | 2019 | 52 | 0.170 |
Why?
|
Arthritis, Rheumatoid | 1 | 2020 | 166 | 0.170 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2020 | 115 | 0.170 |
Why?
|
Logistic Models | 3 | 2018 | 1186 | 0.170 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2019 | 70 | 0.170 |
Why?
|
Osteoporotic Fractures | 1 | 2019 | 38 | 0.170 |
Why?
|
Interleukin-17 | 1 | 2019 | 101 | 0.170 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 199 | 0.170 |
Why?
|
Odds Ratio | 6 | 2017 | 678 | 0.160 |
Why?
|
Ileum | 1 | 2019 | 159 | 0.160 |
Why?
|
Ribotyping | 2 | 2015 | 11 | 0.160 |
Why?
|
Bone Density | 1 | 2019 | 209 | 0.160 |
Why?
|
Incidence | 5 | 2021 | 1577 | 0.160 |
Why?
|
Fractures, Bone | 1 | 2019 | 131 | 0.160 |
Why?
|
Adrenal Cortex Hormones | 1 | 2019 | 263 | 0.160 |
Why?
|
Survival Rate | 1 | 2022 | 1863 | 0.160 |
Why?
|
Paraneoplastic Syndromes | 1 | 2017 | 16 | 0.150 |
Why?
|
Equipment Design | 1 | 2019 | 406 | 0.150 |
Why?
|
Pandemics | 2 | 2020 | 740 | 0.150 |
Why?
|
CTLA-4 Antigen | 1 | 2017 | 135 | 0.150 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 394 | 0.150 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 288 | 0.150 |
Why?
|
Carcinoma, Small Cell | 1 | 2017 | 134 | 0.140 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 1673 | 0.140 |
Why?
|
Glucocorticoids | 2 | 2020 | 352 | 0.140 |
Why?
|
Prevalence | 4 | 2021 | 1239 | 0.140 |
Why?
|
Peptides | 1 | 2020 | 639 | 0.140 |
Why?
|
Itraconazole | 1 | 2016 | 11 | 0.140 |
Why?
|
Paracentesis | 1 | 2016 | 8 | 0.140 |
Why?
|
Ambulatory Care | 1 | 2018 | 181 | 0.140 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2017 | 159 | 0.140 |
Why?
|
Endoscopy | 1 | 2019 | 332 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2017 | 98 | 0.140 |
Why?
|
Registries | 1 | 2020 | 702 | 0.140 |
Why?
|
Ascites | 1 | 2016 | 55 | 0.140 |
Why?
|
Bronchoscopy | 1 | 2017 | 152 | 0.140 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 894 | 0.140 |
Why?
|
Lymph Nodes | 1 | 2019 | 533 | 0.140 |
Why?
|
Wound Healing | 1 | 2018 | 344 | 0.140 |
Why?
|
Antifungal Agents | 1 | 2016 | 117 | 0.130 |
Why?
|
Women's Health | 1 | 2016 | 100 | 0.130 |
Why?
|
Botulinum Toxins | 1 | 2015 | 17 | 0.130 |
Why?
|
Age Factors | 5 | 2018 | 1851 | 0.130 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 413 | 0.130 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2017 | 185 | 0.130 |
Why?
|
Pregnancy Outcome | 1 | 2016 | 247 | 0.130 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2014 | 19 | 0.130 |
Why?
|
Intestinal Obstruction | 1 | 2015 | 88 | 0.120 |
Why?
|
Calcium | 1 | 2019 | 1156 | 0.120 |
Why?
|
History, 18th Century | 1 | 2014 | 23 | 0.120 |
Why?
|
History, 19th Century | 1 | 2014 | 59 | 0.120 |
Why?
|
Pregnancy Complications | 1 | 2016 | 336 | 0.120 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 350 | 0.120 |
Why?
|
Erythrocyte Transfusion | 1 | 2014 | 60 | 0.120 |
Why?
|
Curriculum | 1 | 2018 | 539 | 0.110 |
Why?
|
Feces | 1 | 2015 | 319 | 0.110 |
Why?
|
Calcitonin | 1 | 2013 | 38 | 0.110 |
Why?
|
Tertiary Care Centers | 1 | 2013 | 94 | 0.110 |
Why?
|
Frail Elderly | 1 | 2013 | 71 | 0.110 |
Why?
|
Animals | 4 | 2020 | 26582 | 0.110 |
Why?
|
Primary Health Care | 1 | 2016 | 339 | 0.110 |
Why?
|
Protein Precursors | 1 | 2013 | 143 | 0.110 |
Why?
|
History, 20th Century | 1 | 2014 | 312 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2019 | 1313 | 0.110 |
Why?
|
Immunotherapy | 1 | 2017 | 629 | 0.110 |
Why?
|
Kidney Transplantation | 1 | 2018 | 849 | 0.100 |
Why?
|
Motor Activity | 1 | 2013 | 327 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2020 | 865 | 0.100 |
Why?
|
Child | 6 | 2022 | 6927 | 0.100 |
Why?
|
Postoperative Period | 2 | 2021 | 303 | 0.090 |
Why?
|
Length of Stay | 3 | 2021 | 702 | 0.090 |
Why?
|
CD40 Antigens | 1 | 2009 | 43 | 0.090 |
Why?
|
Databases, Factual | 3 | 2019 | 814 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 2601 | 0.090 |
Why?
|
Recurrence | 3 | 2021 | 1139 | 0.090 |
Why?
|
Interleukin-2 | 1 | 2009 | 249 | 0.080 |
Why?
|
Liver Function Tests | 2 | 2020 | 93 | 0.080 |
Why?
|
Liver Transplantation | 1 | 2016 | 1268 | 0.080 |
Why?
|
Time Factors | 4 | 2018 | 5210 | 0.080 |
Why?
|
Cell Proliferation | 1 | 2014 | 1578 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 3362 | 0.080 |
Why?
|
T-Lymphocytes | 1 | 2014 | 1195 | 0.080 |
Why?
|
Antibodies | 1 | 2009 | 350 | 0.080 |
Why?
|
Remission Induction | 2 | 2019 | 722 | 0.070 |
Why?
|
Interleukin-6 | 2 | 2020 | 256 | 0.070 |
Why?
|
Lung Neoplasms | 1 | 2017 | 2262 | 0.060 |
Why?
|
Child, Preschool | 3 | 2018 | 3612 | 0.060 |
Why?
|
Intubation, Gastrointestinal | 1 | 2023 | 31 | 0.060 |
Why?
|
Michigan | 2 | 2013 | 52 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2016 | 349 | 0.050 |
Why?
|
Disease Progression | 2 | 2018 | 1531 | 0.050 |
Why?
|
United States | 3 | 2022 | 6672 | 0.050 |
Why?
|
Pregnancy | 2 | 2020 | 2894 | 0.050 |
Why?
|
Diverticulum, Esophageal | 1 | 1981 | 5 | 0.050 |
Why?
|
Piperidines | 1 | 2022 | 181 | 0.050 |
Why?
|
Dabigatran | 1 | 2020 | 24 | 0.050 |
Why?
|
Cytoreduction Surgical Procedures | 1 | 2021 | 73 | 0.050 |
Why?
|
Morphinans | 1 | 2019 | 4 | 0.050 |
Why?
|
Cholestasis | 1 | 2020 | 47 | 0.040 |
Why?
|
Bile Acids and Salts | 1 | 2020 | 61 | 0.040 |
Why?
|
Steroids | 1 | 2020 | 177 | 0.040 |
Why?
|
Administration, Oral | 1 | 2020 | 684 | 0.040 |
Why?
|
Organ Size | 1 | 2020 | 364 | 0.040 |
Why?
|
Risk | 1 | 2020 | 674 | 0.040 |
Why?
|
Dermatologic Agents | 1 | 2019 | 71 | 0.040 |
Why?
|
Spinal Fractures | 1 | 2019 | 75 | 0.040 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2019 | 66 | 0.040 |
Why?
|
Naltrexone | 1 | 2019 | 135 | 0.040 |
Why?
|
Narcotic Antagonists | 1 | 2019 | 154 | 0.040 |
Why?
|
Life Expectancy | 1 | 2018 | 86 | 0.040 |
Why?
|
Age Distribution | 1 | 2018 | 204 | 0.040 |
Why?
|
Biological Therapy | 1 | 2018 | 45 | 0.040 |
Why?
|
Databases, Bibliographic | 1 | 2017 | 17 | 0.040 |
Why?
|
Anticoagulants | 1 | 2020 | 408 | 0.040 |
Why?
|
Polyethylene Glycols | 1 | 2019 | 363 | 0.040 |
Why?
|
Data Mining | 1 | 2017 | 42 | 0.040 |
Why?
|
Hepatitis, Chronic | 1 | 2016 | 5 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2018 | 190 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 860 | 0.040 |
Why?
|
Colon | 1 | 2020 | 496 | 0.040 |
Why?
|
Infant | 2 | 2014 | 3046 | 0.040 |
Why?
|
Induction Chemotherapy | 1 | 2017 | 147 | 0.040 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 977 | 0.040 |
Why?
|
Lung Transplantation | 1 | 2018 | 175 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 916 | 0.030 |
Why?
|
Patient Discharge | 1 | 2019 | 300 | 0.030 |
Why?
|
Directive Counseling | 1 | 2016 | 34 | 0.030 |
Why?
|
Cost Savings | 1 | 2016 | 66 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2016 | 98 | 0.030 |
Why?
|
Vomiting | 1 | 2017 | 193 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 746 | 0.030 |
Why?
|
Population Surveillance | 1 | 2016 | 219 | 0.030 |
Why?
|
Hospital Costs | 1 | 2016 | 105 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2018 | 999 | 0.030 |
Why?
|
Sex Factors | 1 | 2018 | 1054 | 0.030 |
Why?
|
Patient Safety | 1 | 2017 | 212 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2020 | 1924 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2020 | 797 | 0.030 |
Why?
|
Cladribine | 1 | 2014 | 35 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 429 | 0.030 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 303 | 0.030 |
Why?
|
Phytohemagglutinins | 1 | 2014 | 22 | 0.030 |
Why?
|
Quality Indicators, Health Care | 1 | 2016 | 144 | 0.030 |
Why?
|
Antigens, CD1 | 1 | 2014 | 35 | 0.030 |
Why?
|
Interleukin-1beta | 1 | 2014 | 78 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 339 | 0.030 |
Why?
|
CD3 Complex | 1 | 2014 | 135 | 0.030 |
Why?
|
Blood Preservation | 1 | 2014 | 10 | 0.030 |
Why?
|
CD28 Antigens | 1 | 2014 | 88 | 0.030 |
Why?
|
Gastroenteritis | 1 | 2014 | 27 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2020 | 2379 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2014 | 138 | 0.030 |
Why?
|
Genetic Markers | 1 | 2014 | 476 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 454 | 0.030 |
Why?
|
Drug Resistance | 1 | 2014 | 256 | 0.030 |
Why?
|
Gastrointestinal Microbiome | 1 | 2020 | 455 | 0.030 |
Why?
|
Chicago | 1 | 2018 | 1379 | 0.030 |
Why?
|
Inflammation Mediators | 1 | 2014 | 154 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2013 | 229 | 0.030 |
Why?
|
Chronic Disease | 1 | 2016 | 971 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2014 | 179 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2014 | 164 | 0.030 |
Why?
|
Calcitonin Gene-Related Peptide | 1 | 2013 | 38 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 526 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 3092 | 0.030 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 286 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2014 | 399 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2014 | 329 | 0.030 |
Why?
|
Mice | 2 | 2020 | 11352 | 0.030 |
Why?
|
Models, Statistical | 1 | 2015 | 574 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 1920 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2014 | 409 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2021 | 2207 | 0.020 |
Why?
|
Macrophage Inflammatory Proteins | 1 | 2009 | 9 | 0.020 |
Why?
|
Chemokine CXCL9 | 1 | 2009 | 7 | 0.020 |
Why?
|
Chemokine CCL5 | 1 | 2009 | 16 | 0.020 |
Why?
|
Receptors, Cytokine | 1 | 2009 | 28 | 0.020 |
Why?
|
Arginase | 1 | 2009 | 16 | 0.020 |
Why?
|
Receptors, CCR2 | 1 | 2009 | 35 | 0.020 |
Why?
|
Chemokines, CC | 1 | 2009 | 34 | 0.020 |
Why?
|
Chemokines | 1 | 2009 | 73 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2014 | 1805 | 0.020 |
Why?
|
Drug Synergism | 1 | 2009 | 303 | 0.020 |
Why?
|
Signal Transduction | 1 | 2020 | 3241 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2014 | 2818 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2009 | 123 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2009 | 1047 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2012 | 1621 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 425 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2013 | 3640 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2012 | 2705 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2009 | 559 | 0.020 |
Why?
|
Mutation | 1 | 2014 | 3968 | 0.010 |
Why?
|